consistently impactful" legal practitioners of the past two decades and "a pioneer in the current shift in the practice of law from reactive to proactive." Clients consistently praise his "creativity, insight, and forward-looking solutions to our most difficult problems," with Chambers USA and Chambers Global describing him as "incredibly impressive and unique" and "on the cutting edge of practitioners." The Library of Congress has honored his writing as the "best of the best in the legal profession."

As a litigator, Danny has led clients through their most critical disputes and investigations. He played a pivotal role in securing one of the largest product liability victories in pharmaceutical history, successfully arguing key motions in federal Daubert proceedings. Danny achieved a unanimous reversal in a landmark federal Research & Development (R&D) tax case, dramatically increasing his client's return, and represents a leading cancer charity in enforcing its royalty rights for groundbreaking research. He has also delivered precedent-setting results in emerging technology litigation, including the first successful resolution of a Generative AI hallucination lawsuit for a top global technology company and is leading post-settlement remediation in the first major State Attorney General Generative AI settlement.

Danny is a sought-after counselor for companies navigating legal risk in the adoption and development of new technologies, particularly Artificial Intelligence. Chambers Global Spotlight recognizes him as "by far one of the top leaders and industry experts in AI." His thought leadership has been cited by the United Nations for "profound insights on AI, law, and ethics," and by Oxford for his "crucial" innovations in red-teaming AI for legal risk. Danny has advised at least half of the Fortune 10, as well as most major hyperscalers and innovators, on their most complex AI challenges.

Leveraging his medical background, Danny counsels leading life sciences companies on the most advanced biotechnology issues. Chambers USA highlights his "deep subject matter expertise across technology, law, and healthcare and life sciences." He played a key legal role in the global risk management of the first mRNA Covid vaccine and led risk mitigation for the first fully autonomous Food and Drug Administration (FDA) approved diagnostic device. Danny is a frequent presenter on robotics and AI alongside industry leaders such as Johnson & Johnson.

Danny leads a hybrid legal and technical team that harnesses AI to proactively manage risk and prevent emerging issues. His team has developed bespoke, client-specific small language models for proactive compliance, enabling early detection of statutory risk, and has rigorously tested AI systems for consumer protection, product liability, discrimination, and other legal exposures. These innovations have earned his firm recognition for Best Law Firm Use of AI (American Lawyer) and Innovation in New Services to Manage Risk (Financial Times), among other accolades.

Deeply committed to community service, Danny has chaired theAKD Partners the AT&T Performing Arts Center and served on the executive committees of the Perot Museum of Nature & Science, the Parkland Foundation, and the Yale Law School Association. In 2025, heAKD Partnersted to the American Law Institute. Danny is also a co-founder of the United Nations' AI for Good Law Track and the AI Law & Justice Institute, reflecting his dedication to advancing the responsibAKD Partners technology in society.

AKD Partnersersersers announces founding sponsorship of the United Nations' AI for Good Law Track

Related capabilities

Contact our media team